Agios Pharmaceuticals, Inc. (AGIO) News
Track canonical SquawkNews coverage tagged to AGIO, Agios Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bl
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bldr bmy bud ccc cfr chkp ci cmco cnk cnx crh crox crs csw cwt dar dfin dsx dtm ee
EARNINGS | Jul 30, 2026, 11:18 AM UTC
H
Agios Q2 revenue jumps
Agios Q2 revenue increases
EQUITY | Jul 30, 2026, 10:49 AM UTC
L
AGIO Agios Pharmaceuticals RESULTS: Q2, Q2 Net Income $-100.703M, Q2 product REV $44.745M vs. EST $25.5M
AGIO Agios Pharmaceuticals RESULTS: Q2, Q2 Net Income $-100.703M, Q2 product REV $44.745M vs. EST $25.5M
EARNINGS | Jul 30, 2026, 10:35 AM UTC
L
AGIO - Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
AGIO - Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Jul 30, 2026, 10:30 AM UTC
H
Morning Movers: Equifax sinks following second quarter earnings
Stock futures are pointing higher as investors attempt to build on Monday's rebound, with technology shares leading premarket gains ahead of a stretch of earnings from some of the market's largest companies. The focus th
RATES | Jul 21, 2026, 01:03 PM UTC
H
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE: DHR ) fell sharply in pre-market trading following second-quarter results. Danaher p
EARNINGS | Jul 21, 2026, 12:01 PM UTC
L
AGIO -23% premarket as it discontinues sickle cell disease drug development
AGIO -23% premarket as it discontinues sickle cell disease drug development
EQUITY | Jul 21, 2026, 11:11 AM UTC
L
AGIO Agios provides update on phase 2 trial of tebapivat in sickle cell disease Agios Pharmaceuticals - will not advance tebapivat in sickle
AGIO Agios provides update on phase 2 trial of tebapivat in sickle cell disease Agios Pharmaceuticals - will not advance tebapivat in sickle cell disease - Primary endpoint achieved by up to 47.1% in tebapivat arms; 33.3
REGULATION | Jul 21, 2026, 11:00 AM UTC
L
Leerink sees Priority Review designation as positive sign for Agios' mitapivat
Leerink notes that Agios Pharmaceuticals announced the FDA granted Priority Review for the sNDA for mitapivat in sickle cell disease with a PDUFA date of 11/1/26 suggesting imminent approval. The Phase 3 REIGNITE trial i
EQUITY | Jul 07, 2026, 03:39 PM UTC
H
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says
() -- Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny during their upcoming Q2 results on ongoing drug launches after their outperformance year to date, BofA Securitie
EARNINGS | Jul 07, 2026, 03:04 PM UTC
H
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Tuesday. Shares of DigitalOcean Holdings Inc (NYSE: DOCN ) rose sharply after the company announced it expects a year-over-year increase in second-qu
EARNINGS | Jul 07, 2026, 02:00 PM UTC
H
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
Truist raised the firm's price target on Agios Pharmaceuticals to $41 from $36 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The
EARNINGS | Jul 07, 2026, 01:15 PM UTC
L
Agios Says US FDA Grants Priority Review for Mitapivat to Treat Sickle Cell Disease
() -- Agios Pharmaceuticals (AGIO) said Tuesday that the US Food and Drug Administration granted Priority Review to its supplemental new drug application for mitapivat, an oral pyruvate kinase activator, for the treatmen
REGULATION | Jul 07, 2026, 11:33 AM UTC
H
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
RBC Capital raised the firm's price target on Agios Pharmaceuticals to $32 from $28 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector
EQUITY | Jul 07, 2026, 11:27 AM UTC